A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Mounjaro and Zepbound are by far Lilly's fastest ... Verzenio's performance in 2024 underscores how expanded indications for medications can accelerate their performance and help contribute ...

and is in development for four additional indications, including chronic kidney disease. Similarly, tirzepatide has been approved for type 2 diabetes under the name Mounjaro and for obesity under ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Similarly, Mounjaro (tirzepatide ... Novo Nordisk's efforts to expand the indications for its existing products, particularly semaglutide, present significant growth opportunities.

Pharmacists say they are aware of people being wrongly prescribed the drugs who have previously had eating disorders, or ...

Mounjaro had a very strong year growing share ... This is total prescriptions across all indications in US incretin market, black line seems to be going up into the right at an aggressive rate.

The National Pharmacy Association (NPA) has written to regulators calling for tougher rules to be introduced around sale of ...

The company has supplied the drugs to 200,000 people ... bowed to demands from the NHS to restrict access to Mounjaro to just 200,000 of 3.4 million eligible patients over the first three years ...